Zimberelimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. MW :144.72 KD.